STEERING COMMITTEE FOR THE UK STEM CELL BANK AND FOR THE USE OF STEM CELL LINES

APPLICATION FORM TO DEPOSIT A HUMAN STEM CELL LINE IN THE UK STEM CELL BANK

Notes to Depositors

(Please read these notes before completing the application form)

Submit your completed application form by email to the Secretary of the Stem Cell Steering Committee:

stemcellsecretary@headoffice.mrc.ac.uk

For general information contact:

The Secretary to the Steering Committee for the UK Stem Cell Bank and for the Use of Stem Cell Lines, 2nd Floor David Phillips Building,

Polaris House North Star Avenue. Swindon, Wiltshire SN2 1FL UK For scientific information contact:

Tel: +44(0)1793 416349

For scientific information cor

Dr Paul Colville-Nash: paul.colville-nash@headoffice.mrc.ac.uk

or Dr Charles Hunt:

enquiries@ukstemcellbank.org.uk

The following documents must accompany your application:

- A copy of the donor consent form (see below see Note 2) and information provided to donors
- A copy of ethics committee approval (or equivalent)
- A copy of any published scientific papers related to the derivation and/or characterization of the stem cell line
- A one page CV for the Principle Investigator
- A one page CV for the Designated Individual (only required for UK cell lines intended for human application)

If submitting electronically, PDF files of WORD documents are acceptable. Paper copies may be submitted to the Secretary, but must be accompanied by a completed copy of the application form.

If you are including a copy of the signed donor consent form with the application, you <u>must</u> contact the Secretary to the Stem Cell Steering Committee to request a pre-addressed envelope for submission of this document.

It is important that this application is understandable by lay members and all abbreviations explained.

Notes to Sections

Note 1: Stem cell lines suitable for clinical/therapeutic use i.e. intended for human application under the Human Tissue (Quality and Safety for Human Application) Regulations (2007) will have been derived under conditions that make them suitable for use in humans. This includes facilities, growth media and any associated feeder cell layers and the conditions under which these were grown. Cell lines suitable for clinical/therapeutic application may also be used for research

Note 2: Any restrictions made by the donor(s) on the utilisation of the cell line must be detailed in section 5.

Note 3: The Register of Steering Committee approved stem cell lines can be viewed on the UK Stem Cell Bank website at <u>www.ukstemcellbank.org.uk</u>. If the line is on the approved list please provide the application number assigned by the UK Steering Committee. The National Institutes of Health Registry is available at <u>http://stemcells.nih.gov/research/registry</u>; for other lines approved for use by NIH which do not appear in this registry, please provide evidence. Where requested lines include both registered and unregistered lines, you may be advised to submit these as separate requests to facilitate the approval process.

Note 4: For the purpose of traceability, Human Fertilisation and Embryology Authority (HFEA) licence holders are requested to provide both their licence number and the name and centre number of the unit providing the embryo(s) from which the hES cell line(s) were derived.

Note 5: For cell lines intended for human application, the Designated Individual for the centre in which the cell line was derived is requested to provide both their Human Tissue Authority (HTA) license number and a list of activities conducted under the licence.

Note 6: The Steering Committee considers all applications on a case by case basis and appreciates that in the area of consent that there may be occasions when not all the criteria listed in Section 3 are fulfilled. The Steering Committee reserves the right to ask for original documentation if considered necessary.

Note 7: The Code of Practice for the UK Stem Cell Bank and the Use of Stem Cell Lines can be found on both the UK Stem Cell Bank and the Medical Research Council websites.

APPLICATION FORM TO DEPOSIT A HUMAN STEM CELL LINE IN THE UK STEM CELL BANK

SECTION 1

General Information

Complete all boxes

1.1 Name(s) of cell line(s):	1.2 Number of cell lines for which application is made:
1.3 Name and title of Principle Investigator:	1.4 Name of owner of the cell line(s)
1.5 Country of origin of the cell line(s):	1.6 Origin of the cell line(s):
If Non-UK indicate country of origin	Embryonic 🗌 Fetal 🗌 Adult 🗌
1.7 Grade of cell line (see note1):	
Clinical/therapeutic (EUTCD compliant)	Laboratory Research
1.8 Is the cell line listed on the Register of Steering Committee Approved Stem Cell Lines (see note 3):	1.9 Is the cell line listed on the NIH Registry (see note 3)
Yes 🗌 🛛 No 🗌	Yes 🗌 No 🗌
If Yes provide original SCSC Application number	

SECTION 2

Applicant Details

2.1 Name and title of Principle Investigator:	Post held:
Address:	Telephone:
	Fax:
	E-mail:
2.2 Name and title of the provider of / contact for the cell line (Complete only if different from 2.1 above):	Post held:
Address:	Telephone:
	Fax:
	E-mail:

2.3 Name of person with authority to deal with the Materials Transfer Agreement		
Address:	Telephone:	
	Fax:	
	E-mail:	
2.4 Name of Authorised Signatory for owner(s) of the	e cell line:	
Address:	Telephone:	
	Fax:	
	E-mail:	
2.5 Name of Authorised Signatory for the Host Instit	ution:	
Address:	Telephone:	
	Fax:	
	E-mail:	
2.6 This question applies ONLY to UK CENTRES DERIVIN	G EMBRYONIC STEM CELL LINES (see note 4):	
Name and title of HFEA license holder (Complete only if	Post held:	
different from 2.1 above).		
Address:	Telephone:	
	Fax:	
	E-mail:	
2.7 This question applies ONLY to UK CENTRES DERIVIN	G EMBRYONIC STEM CELL LINES (see note 4):	
HFEA licence number for derivation centre		
Centre from which embryo(s) were obtained:	HFEA centre number (see note 4)	

FOR OFFICE USE ONLY

SCSC Application No.

2.8 This question applies ONLY to UK CENTRES DEPOSITING STEM CELL LINES FOR HUMAN APPLICATION UNDER HTA LICENCE (i.e. cell lines intended for human application under the Human Tissue (Quality and Safety for Human Application) Regulations 2007 see note 5).					
Name and title of HTA Designated Individual:		Post held:			
Address:			Telephone:		
			Fax:		
			E-mail:		
2.9 This question applies ONLY to UK CENTRES DEPOSITING STEM CELL LINES FOR HUMAN APPLICATION UNDER HTA LICENCE (i.e. cell lines intended for human application under the Human Tissue (Quality and Safety for Human Application) Regulations 2007 see note 5).					
HTA licence numbe	er				
Indicate below the	activities that t	he centre carries	out under licence	or third party agre	ement
Procurement	Yes 🗌	No 🗌	Testing	Yes 🗌	No 🗌
Processing	Yes 🗌	No 🗌	Storage	Yes 🗌	No 🗌
Import/Export	Yes 🗌	No 🗌	Distribution	Yes 🗌	No 🗌

SECTION 3

Details of Consent

SECTION 3A (UK Embryonic Stem Cell Lines Only)

Complete this section ONLY IF the stem cell line(s) is of embryonic origin AND was derived in the UK

THIS SECTION SHOULD BE COMPLETED BY THE HFEA LICENCE HOLDER

Complete <u>ALL</u> boxes in this section.

3.1 Was the project leading to to approv committee:	ve the derivation of the o	cell lines		
Yes [N	•	If you answered YES you must supply a copy of the approval letter with your application	
3.2 Have you clarified with the consenting clinician that informed consent, in line with UK guidelines and requirements, has been given including for the use of the embryo(s) for the purpose of deriving a stem cell line(s):				
Yes [No		If you answered YES you must supply a copy of the donor consent formwith your application	
3.3 Have any constraints been imposed	I on the donation by the	donor(s)	
Yes [No		If you answered YES please see Note 2 and complete section 5	
Signature:	Print Name:		Date:	

SECTION 3B (UK Non-embryonic Stem Cell Lines Only)

<u>Complete this section ONLY IF the stem cell line(s) is of non-embryonic origin AND was derived in the UK</u> THIS SECTION SHOULD BE COMPLETED BY THE PRINCIPLE INVESTIGATOR

Complete <u>ALL</u> boxes in this section.

3.4 Was the project leading to the derivation of the cell lines(s) approved by an ethics committee:					
Yes		o 🗌	If you answered YES you must supply a copy of the approval letter with your application		
3.5 Have you clarified with the consen has been given:	3.5 Have you clarified with the consenting clinician that informed consent, in line with UK best practice, has been given:				
Yes		o 🗌	If you answered YES you must supply a copy of the donor consent form with your application		
3.6 Have any constraints been impose	d on the donation by the	donor(s)		
Yes		o 🗌	If you answered YES please see Note 2 and complete section 5		
Signature:	Print Name:		Date:		

SECTION 3C (All UK Stem Cell Lines for Human Application)

<u>Complete this section ONLY IF the stem cell line(s) is intended for human application AND was derived in the UK</u>

THIS SECTION SHOULD BE COMPLETED BY THE DESIGNATED INDIVIDUAL UNDER THE HTA LICENCE

Complete <u>ALL</u> boxes in this section.

3.7 Have you and the consenting clinician consent	n complied with H	TA Direction	s with respect to informed
Yes 🗌		No 🗌	
3.8 Does the consent obtained include ex	plicit consent to t	he use of the	e cells in human application
Yes 🗌		No 🗌	
3.9 Have any constraints been imposed o	on the donation by	the donor(s)
Yes 🗌		No 🗌	If you answered YES please see Note 2 and complete section 5
Signature:	Print Name:		Date:

SECTION 3D (Non-UK Derived Stem Cell Lines Only)

<u>Complete this section ONLY IF the stem cell line(s) are of embryonic or somatic origin AND were derived</u> outside the UK AND are not listed on either the UK Register of Steering Committee Approved Stem Cell Lines or the NIH Registry (see note 3);

Complete <u>ALL</u> boxes in this section (see note 6).

2.10	the project leading to th	a darivation of the col	l lines(s) en	proved by on othics	
3.10 Was the project leading to the derivation of the cell lines(s) approved by an ethics committee (or equivalent): If you answered YES you must supply a copy of					
	Yes		No 🗌	the approval letter with your	application
3.11 Have	any constraints been im	posed on the donatio	n by the do	nor(s)	
	Yes		No 🗌	If you answered YES please s complete section 5	see Note 2 and
The following	criteria constitute best p	practice in the UK for i	nformed co	onsent.	
3.12 At the	e time of consenting, wa	s the donor(s) informe	ed:		
	pecific research project, in mbryos or cells derived fro		ay be perfor	med as part of the lice	ensed research
			Yes		No 🗌
ii that any ste	em cell lines created may o	continue indefinitely and	d may be use	ed in many different re	esearch projects
			Yes		No 🗌
iii that the de	cision whether to donate w	would not affect their tre	atment in an	ny way	
			Yes		No 🗌
iv about whe	ther the embryos/cells wou	uld be reversibly or irrev	ersibly anon	nymised and the implic	cations of this
			Yes		No 🗌
v whether ar	ny information will be fed b	ack to the donor(s)			
			Yes		No 🗌
vi that the do	nors may vary or withdraw	v their consent until the	point the em	bryos/cells are used i	n the project
			Yes		No 🗌
	the embryo/cells has beer by stem cell lines derived	n used in the project, the	e donor(s) ha	ave no control over ar	y use of the
	-		Yes		No 🗌
	cell lines derived in this p ding long term storage an			em Cell Bank and the	implications of
			Yes		No 🗌
ix that stem of	cell lines may not be gener	rated where the consen	t places a co	onstraint on future use	
			Yes		No 🗌
x that cell lin	es may be used for comm	ercial purposes, but tha	at donor(s) w	vill not benefit financia	lly from this
	·		Yes		No 🗌
xi that cell lin	es derived or discoveries	made from them may b		ut donor(s) will not fin	
		induo iroin thom may b	Yes		
	e the intention was to derivential for future use of the	•	al human app	Dication, donors have	
			Yes		No 🗌
xiii regarding	g how the research was fu	nded, including any ber		av accrue to research	
	artments/companies				
			Yes		No 🗌

FOR OFFICE USE ONLY

SCSC Application No.

3.13 Name of licensing authority or body accrediting the derivation centre (in the country of origin):			
Address:	Telephone:		
	Fax:		
	E-mail:		
3.14 Licensing or Accreditation number for the li	cence holder / derivation centre (in the country of origin):		
3.15 Name of licensing authority or body accrediting the donation centre (the centre, in the country of origin, from which the embryo(s) or tissue (in the case of non-embryonic cell lines) was obtained – if different from 3.13 above):			
Address:	Telephone: Fax:		
	E-mail:		
3.16 Licensing or Accreditation number for the donation centre (in the country of origin):			
Address:	Telephone:		
	Fax:		
	E-mail:		

SECTION 4

Details of Cell Line(s)

Complete all boxes in this section (failure to do so in sufficient detail may delay the application)

4.1 Description and characterisation of the tissue of origin			
4.2 Was the tissue of origin fresh or cryopreserved	1?		
	Fresh	Cryopreserved	
4.3 Date of donation	4.4 Date used or	thawed (if frozen)	
4.5 Was the stem cell line derived in facilities accredited by the host country under the EU Tissue and Cells Directives (or similar recognized standard and if derived outside the EU; please specify standard if not EUTCD)			
	Yes 🗌	No 🗌	
4.6 Was the stem cell line derived within a quality system accredited by the host country under EU Tissue and Cells Directives (or similar recognized standard and if derived outside the EU; please specify standard if not EUTCD)			
	Yes 🗌	No 🗌	
4.7 Is the cell line intended for basic research?	4.8 Is the cell line	suitable for use in animals	
Yes 🗌 🛛 No 🗍	Yes 🗌	No 🗔	

FOR OFFICE USE ONLY					
SCSC Application No.					
4.9 Could the cell line be used for human therapy? (<u>Onl</u> y answer Yes if you ticked Yes in 4.5 and 4.6 above)	4.10 Has the cell line been genetically modified? Yes No				
Yes 🗌 No 🗌					
4.11 Details of the morphological characteristics i peer reviewed publication only cite reference)	······································				
4.12 Details of differentiation characteristics and functional analysis of the cell line (<i>If this is covered in an accompanying peer reviewed publication only cite reference</i>)					
4.13 Details of the determination of pluripotency (<i>If this is covered in an accompanying peer reviewed publication only cite reference</i>)					
4.14 Markers used to characterise cell line and result (Indicate passage level at which marker studies were carried out)					
4.15 Was clonal analysis performed Yes No	4.16 If Yes indicate how it was conducted and outcome				

SECTION 5

Restrictions

5.1 If there are any constraints placed on donation by the donor(s) (i.e. your answer to	o Section 3.3, 3.6,
3.9 or 3.11 was YES), please specify restrictions here	

SECTION 6

Embargo

The stem cell line will be listed on the Bank Website. It is possible for the depositor to request that release of the cell lines to accessors, for research in a restricted field, is embargoed for 12 months. In exceptional cases, the Stem Cell Steering Committee may be prepared to consider embargo periods for up to 5 years. (e.g. it would be possible to seek to embargo for 12 months the use of a cell line to generate dopamine producing cells for Parkinson's Disease, but it would not be acceptable to try to embargo for 12 months the use of the cell line for any research into neuroscience).

6.1 If you wish to request an embargo, please specify the restricted field and fully justify the	erequest
(the case and restricted field must be approved by the steering committee)	

SECTION 7

Declaration

By submitting this application to the secretary to the Stem Cell Steering Committee, I confirm that:

- i. the information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
- ii. I have read and understood the Code of Practice for the UK Stem Cell Bank and the Use of Stem Cell Lines and I agree to abide by it (see note 7)

Signed by the Principal Investigator (section 2.1), Cell Line Provider (section 2.2), or HFEA Licence Holder (section 2.6) – delete as applicable	Signed by Designated Individual (section 2.8, where cell lines are intended for human application)
Date:	Date:

Signed by the Authorised Signatory on behalf of Host Institution (section 2.5)	Signed by the Authorised Signatory on behalf of Owner of the cell line (section 2.4; if different from Host Institution)
Date:	Date: